Gastric cancer is the second most common malignancy in Korea, where its incidence is among the highest in the world 1 . Although outcomes have improved, mainly owing to government-supported cancer screening, many patients still present with symptomatic disease and die from their cancer. By 2007, the Gastric Cancer Centre at the National University Hospital in Seoul had a surgical experience involving more than 20 000 patients. The database, developed over the past 20 years, contains details of more than 10 000 patients with gastric cancer, and was used to inform the revised seventh AJCC/UICC TNM classification of gastric cancer 2 and to formulate a nomogram to predict individual patient survival 3 . A number of major initiatives reflect the benefits of such a large institutional patient volume, which facilitates research at the bedside, in the operating theatre and in the laboratory.
High-volume clinical activity has encouraged participation in major RCTs that could influence the global management of gastric cancer. For stage IV gastric cancer, the REGATTA trial has been reported recently 5 , demonstrating that gastrectomy followed by chemotherapy does not confer a survival benefit compared with chemotherapy alone in advanced gastric cancer with a single non-curable factor.
Large institutional volumes also facilitate research in the operating theatre. Radical gastrectomy with lymph node dissection has long been considered the principal treatment for gastric cancer, with an emphasis on the extent of perigastric lymph node dissection. Little attention has been paid to the fact that, during radical gastrectomy, the surgeon opens the gastric lumen for resection and anastomosis. If cancer cells are detached from the primary site into the lumen, this might be a source of dissemination into the peritoneal cavity. Similarly, when lymph nodes are involved by cancer cells, inadequate closure of draining lymphatics during dissection might also result in cancer cell spillage into the peritoneal cavity. Research at this institution has demonstrated clearly that cancer cell spillage from lymphovascular channels can occur, providing support for the principle in oncological surgery that these vessels should be controlled properly, to prevent this event 6 . Recently there has been increasing interest in robotic surgery for gastric cancer. A number of clinical studies have been undertaken to identify the characteristics, advantages and limitations of a robotic approach. These include observational studies looking at manual dexterity 7, 8 as well as a phase II study investigating vessel sealing in robotic surgery. Novel techniques that have been promising in the laboratory may also come to clinical fruition. In the area of imageguided surgery, the near-infrared fluorescence tracers pullulan polymer and indocyanine green-γ-glutamic acid complex have been used successfully in animal models, and could find application in sentinel node navigation surgery 9 . In the era of laparoscopic surgery, visual augmentation using a near-infrared camera is an easy add-on function that can facilitate surgical dissection in terms of extent of lymph node dissection, and provide information on gut perfusion. Based on this large volume of clinical activity, a gastric cancer biorepository has been developed, providing access to tissues from more than 1200 patients with gastric cancer in combination with clinical and pathological data. Investigation of genetic mechanisms in the development of gastric cancer has led to the recognition of profiles strongly associated with lymphatic metastasis. The identification of candidate genes that show meaningfully differential expression between patients with small tumours with many positive metastatic lymph nodes (T2 N3) and those with bulky and deep tumours with no lymph node metastasis (T3 N0) might form the basis of a tailored treatment approach 10 . In collaboration with Vanderbilt University in Nashville, Tennessee, USA, work on parietal cell loss that leads to spasmolytic polypeptide-expressing metaplasia (SPEM) in gastric cancer has disclosed a marker of good prognosis (CDH-17) in early gastric cancer 11 . Personalized approaches to gastric cancer management are likely to rely increasingly on a variety of 'omic technologies. Personalized treatment might be achieved through the development of a predictive humanized animal model. Collaborations between basic biomedical and clinical sciences have led to the successful creation of the murine gastric cancer PDX model incorporating gastric cancer 12 .
Although the low mortality from gastric cancer seen in Korea may in part be explained by early detection as a result of nationwide endoscopic screening, this may not be feasible in Western countries where the incidence of disease is much lower. The development of new non-invasive diagnostic modalities, including multitarget stool DNA testing 13 , or the recognition of gastric cancerspecific volatile organic compounds by mass spectrometry undertaken in a high-incidence population such as Korea might, however, be a more realistic approach in the West.
Taking clinical observations to the laboratory and 'translating' basic science for clinical application is facilitated in a high-incidence environment. Gastric cancer research in Korea can benefit not only the local population, but should have relevance to the global population affected by this disease.
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